TABLE OF CONTENTS
Volume 80, Issue 5 (November 2006)
Pharmacokinetics and Drug Disposition |
Clinical Trial |
Letters to the Editor |
Correction |
Obituary
Pharmacogenetics and Genomics
ABCB1 gene polymorphisms are not associated with treatment outcome in elderly acute myeloid leukemia patients
Bronno van der Holt MSc, Marry M. Van den Heuvel-Eibrink PhD, Ron H. N. Van Schaik PhD, Ilse P. van der Heiden MSc, Erik A. C. Wiemer PhD, Paula J. M. Vossebeld PhD, Bob Löwenberg PhD and Pieter Sonneveld PhD
Clin Pharmacol Ther 80: 427-439; doi:10.1016/j.clpt.2006.07.005
Transcriptional profiling of genes induced in the livers of patients treated with carbamazepine
Mikael Oscarson MD, PhD, Ulrich M. Zanger PhD, Oktay F. Rifki MSc, Kathrin Klein PhD, Michel Eichelbaum MD and Urs A. Meyer MD
Clin Pharmacol Ther 80: 440-456; doi:10.1016/j.clpt.2006.08.013
CYP2A6 genotype and the metabolism and disposition kinetics of nicotine
Neal L. Benowitz MD, Gary E. Swan PhD, Peyton Jacob III PhD, Christina N. Lessov-Schlaggar PhD and Rachel F. Tyndale PhD, MSc
Clin Pharmacol Ther 80: 457-467; doi:10.1016/j.clpt.2006.08.011
High-dose methotrexate in pediatric acute lymphoblastic leukemia: Impact of ABCC2 polymorphisms on plasma concentrations
Thomas Rau MD, Birgit Erney, Ralf Göres MD, Thomas Eschenhagen MD, Jörn Beck MD and Thorsten Langer MD
Clin Pharmacol Ther 80: 468-476; doi:10.1016/j.clpt.2006.08.012
Pharmacokinetics and Drug Disposition
Disposition and sterol-lowering effect of ezetimibe are influenced by single-dose coadministration of rifampin, an inhibitor of multidrug transport proteins
Stefan Oswald PhD, Thomas Giessmann MD, Dieter Luetjohann PhD, Danilo Wegner, Dieter Rosskopf MD, Werner Weitschies PhD and Werner Siegmund MD
Clin Pharmacol Ther 80: 477-485; doi:10.1016/j.clpt.2006.07.006
Impact of P-glycoprotein on clopidogrel absorption
Dirk Taubert MD, PhD, Nicolas von Beckerath MD, Gundula Grimberg MS, Andreas Lazar MD, Norma Jung MD, Tobias Goeser MD, Adnan Kastrati MD, Albert Schömig MD and Edgar Schömig MD
Clin Pharmacol Ther 80: 486-501; doi:10.1016/j.clpt.2006.07.007
Voriconazole, but not terbinafine, markedly reduces alfentanil clearance and prolongs its half-life
Teijo I. Saari MD, Kari Laine MD, Kari Leino MD, Mika Valtonen MD, Pertti J. Neuvonen MD and Klaus T. Olkkola MD
Clin Pharmacol Ther 80: 502-508; doi:10.1016/j.clpt.2006.07.008
Rifampin induces alterations in mycophenolic acid glucuronidation and elimination: Implications for drug exposure in renal allograft recipients
Maarten Naesens MD, Dirk R. J. Kuypers MD, PhD, Frank Streit PhD, Victor W. Armstrong MD, PhD, Michael Oellerich MD, Hon MD, Kristin Verbeke PharmD, PhD and Yves Vanrenterghem MD, PhD
Clin Pharmacol Ther 80: 509-521; doi:10.1016/j.clpt.2006.08.002
Effect of grapefruit juice on cytochrome P450 2A6 and nicotine renal clearance
Janne Hukkanen MD, PhD, Peyton Jacob III PhD and Neal L. Benowitz MD
Clin Pharmacol Ther 80: 522-530; doi:10.1016/j.clpt.2006.08.006
Sex differences in CYP3A activity using intravenous and oral midazolam
Maylee Chen PharmD, Lei Ma MS, George L. Drusano MD, Joseph S. Bertino Jr PharmD and Anne N. Nafziger MD, MHS
Clin Pharmacol Ther 80: 531-538; doi:10.1016/j.clpt.2006.08.014
Clinical Trial
Initial 48-hour acid inhibition by intravenous infusion of omeprazole, famotidine, or both in relation to cytochrome P450 2C19 genotype status
Mitsushige Sugimoto MD, PhD, Takahisa Furuta MD, PhD, Naohito Shirai MD, PhD, Mutsuhiro Ikuma MD, PhD, Akira Hishida MD, PhD and Takashi Ishizaki MD, PhD
Clin Pharmacol Ther 80: 539-548; doi:10.1016/j.clpt.2006.08.010
Letters to the Editor
Impact of CYP2C9*3/*3 genotype on the pharmacokinetics and pharmacodynamics of piroxicam
Jamila A. Perini PharmD and Guilherme Suarez-Kurtz MD, Doct Med
Clin Pharmacol Ther 80: 549-551; doi:10.1016/j.clpt.2006.08.003
Tolerability of 
-blockers metabolized via cytochrome P450 2D6 is sex-dependent
Petra A. Thürmann MD, Sara Haack, Ulrike Werner PhD, Jacek Szymanski, Grit Haase, Bernd Drewelow MD, Ilselore R. Reimann MD, Marion Hippius PhD, Werner Siegmund MD, Karen May PhD and Joerg Hasford MD
Clin Pharmacol Ther 80: 551-553; doi:10.1016/j.clpt.2006.08.004
Warfarin dose requirement for patients with both VKORC1 3673A/A and CYP2C9*3/*3 genotypes
Tsuyoshi Fukuda PhD, Tomoko Tanabe MS, Masako Ohno PhD, Katsuhiko Tougou MS, Yasushi Fujio MD, PhD, Junichi Azuma MD, Isamu Yamamoto MD, PhD and Akira Takeda MD, PhD
Clin Pharmacol Ther 80: 553-554; doi:10.1016/j.clpt.2006.08.005
Possible role for human leukocyte antigen haplotype in rofecoxib-associated acute pancreatitis and cholestatic hepatitis
Ken Sato MD, PhD, Eijirou Yamada MD, PhD, Yutaka Uehara MD, PhD, Hitoshi Takagi MD, PhD and Masatomo Mori MD, PhD
Clin Pharmacol Ther 80: 554-555; doi:10.1016/j.clpt.2006.08.007
The 2988G>A polymorphism affects splicing of a CYP2D6 minigene
Thomas Rau MD, Silke Diepenbruck, Ines Diepenbruck and Thomas Eschenhagen MD
Clin Pharmacol Ther 80: 555-558; doi:10.1016/j.clpt.2006.08.008
Reply
Andrea Gaedigk MS, PhD and J. Steven Leeder PharmD, PhD
Clin Pharmacol Ther 80: 558-560; doi:10.1016/j.clpt.2006.08.009
Correction
Correction FREE
Clin Pharmacol Ther 80: 560; doi:10.1016/j.clpt.2006.09.015
